The role of the psychogenic factor in the development of malignant tumours

Minsk
January 23-24, 2018
Oleg Bukhtoyarov
MD,
Chief physician, “Medical Center 39”
Kaliningrad, Russia

RESOURCES
in 39 scientific databases:
•24.8 million scientific works
• 55,607 books
• 322 scientific journals (2015)
 127 $ billion/year – treatment (2014 г.)
 458 billion/year – treatment (2030 г.)
 90 billion/year – drugs
 1 849 drugs in development
RESULT/PROGNOSIS
MORBIDITY
14 million – 2012 / 22 million. – 2032.
MORTALITY
8,2 million – 2012/ 13 million– 2032
ECONOMIC DAMAGE
1,16 $ trillion – 2010 /? $ trillion
National Cancer Program in 64 Russian Regions (2009-2014)
 47 billion rubles spent
The annual mortality rate decreased by 1%
Folded on January 01, 2015

CANCER ETIOLOGY
(common scientific opinion)
1. Chemical carcinogens (80%)
2. Physical carcinogens (15%)
3. Biological carcinogens (5%)
DETECTION OF THE ETIOLOGY
OF CANCER
(in clinical practice)
Not conducted
ETIOTROPIC TRATMENT OF
CANCER
(in clinical practice)
Not available
Existing and currently developed methods of treatment of malignant
tumors (chemotherapy, radiotherapy, virotherapy) are based on the
use of carcinogens!

PATHOGENESIS OF MALIGNANT TUMORS Is the process of damage to the genetic apparatus
of the cell, leading to the appearance of a tumor
(common scientific opinion)
ИНИЦИАЦИЯ ПРОМОЦИЯ ТРАНСФОРМАЦИЯ ПРОГРЕССИЯ
PATHOGENETIC THERAPY OF MALIGNANT
TUMORS
Methods of gene therapy for cancer are only
being developed and their application in
clinical practice is a matter of the future!
DIAGNOSTICS OF PATHOGENETICALLY
IMPORTANT DAMAGES OF THE GENOM
In broad clinical practice
NOT CONDUCTED
So what does modern therapy for malignant
tumors target?
(MOLECULAR-GENETIC LEVEL OF THE ORGANISM)
NOT AVAILABLE

Modern scientific opinion
All oncological processes are the result of the functioning of cancer cells!
Уклонение опухоли от иммунного надзора
Угнетение противоопухолевого иммунитета
Воспаление, продукция оксидантов
Ангиогенез, опухолевый рост, метастазирование
Генетическая нестабильность, сокращение длины теломер и др.Раковые клетки
Modern clinical view
Cancer treatment targets the consequences of the functioning of cancer cells:
ХИРУРГИЯ
ХИМИОТЕРАПИЯ
РАДИОТЕРАПИЯ
Элиминация опухолевых клеток из организма
ТАРГЕТНАЯ
ТЕРАПИЯ
ИММУНО-
ТЕРАПИЯ
Иммунное уклонение опухоли, ангиогенез и др.
Угнетение противоопухолевого иммунитета

CLINICAL
ONCOLOGY
FUNDAMENTAL
ONCOLOGY
2. The possibility of malignant tumor development without damage to cell DNA.
1. Spontaneous regression of malignant tumors of any histological type.
4. The absence of malignant tumors with the constant formation of malignant
tumor cells in the body (up to 100 million cells daily).
These and many other scientific facts are inexplicable from the standpoint
of the existing view of the cause of malignant tumors, as a pathology of
the genetic apparatus of the cell
3. Reversibility of the cancerous genotype of cells to normal one.

Угнетение
противоопухолевого
иммунитета
Возникновение опухоли
Развитие опухоли
Рецидив опухоли
Oppression of antitumor immunity is the main condition
for the existence of malignant tumors
Prostate cancer cellCell DNA damage

METHODS OF
ACTIVATION(immune
therapy)
 Adjuvant
immunotherapy
 Cytokinotherapy
 LAC Therapy
 TIL-therapy
 DNA vaccine
 Dendritic vaccines
 Peptide vaccines
 Use of growth factors
 Target therapy
 Chimeric antibody
therapy
 The use of costimulatory
molecules
 Alternative
immunotherapy (Coley’s
vaccine, etc.)
 Gene therapy
 . . .
Suppression of
antitumor immunity
EFFICIENCY
IN THE EXPERIMENT
(on animal models):
High
30% -100%
EFFICIENCY IN
WIDE CLINICAL
PRACTICE:
1. Without effect
2. Deterioration
THERE IS
a constantly acting systemic factor capable of inducing persistent
inhibition of antitumor immunity and stimulation of malignant
tumor growth
?
APPROBATION IN
CLINICAL PRACTICE:
Efficiency
up to 30%

The phenomenon of spontaneous cancer regression is the complete or
partial, temporary or permanent disappearance of all or some
parameters of a diagnosed malignant tumor disease in the absence of
medical treatment or treatment that does not have a sufficient
explanation for tumor regression.
ЖИВОТНОЕ
до 80%
ЧЕЛОВЕК
0,00071%
The main factor in the development of
malignant tumor disease in humans is
higher nervous activity

Chemical
Benzpyren
Asbestos
Aflatoxin
Arsenic, etc.
80%
Physical
Ultraviolet
Ionizing radiation
Non-ionizing
radiation
Mechanical impact
15%
Biological
Viruses
Bacteria
Parasites
5%
EXOGENOUS CARCINOGENS
DNA damage
• Mutations
• Inhibition of DNA repair
• Activation of tumor-promoting
genes
• Inactivation of tumor suppressor
genes
• Changes in the binding of
transcription factors
• Many other genetic disorders
Immunity suppression
• Disorders of the effector function of
NK cells, CTL, macrophages
• Th1 / Th2, M1 / M2 Balance Violation
• Intercellular interactions disorders
• Cytokines synthesis, production and
signaling disorders
• Many other immunological disorders
CARCINOGENESIS

Повреждение ДНК
• Mутации
• Ингибирование восстановления ДНК
• Aктивац. опухолепромоторн. генов
• Инактивация опухолесупрессор. генов
• Изменения в связывании
транскрипционных факторов
• Другие генетические нарушение
Иммуносупрессия
• Нарушения эффекторных функций
NK-клеток, CTL, макрофагов
• Нарушение баланса Th1/Th2, М1/М2
• Наруш. межклеточных взаимодействий
• Нарушение синтеза, продукции и
сигналинга цитокинов
• Другие иммунологические нарушения
К A Н Ц Е Р O Г E Н E З
ОПУХОЛЕВАЯ БОЛЕЗНЬ
Дезинтеграция систем мозга
Передняя доля
гипофиза
Симпат. спино-
мозгов. нервы
Oксидативно-нитрозативный стресс
Гормоны стресса (глюкокортик., катехоламины)
Кора надпоч. Мозг. в-во надп.
Гипоталамус
Ишемия тканей. Meтаболические нарушен.

DNA damage
• Mutations
• Inhibition of DNA repair
• Activation of tumor-promoting
genes
• Inactivation of tumor suppressor
genes
• Changes in the binding of
transcription factors
• Many other genetic disordersе
Иммуносупрессия
• Нарушения эффекторных функций
NK-клеток, CTL, макрофагов
• Нарушение баланса Th1/Th2, М1/М2
• Наруш. межклеточных взаимодействий
• Нарушение синтеза, продукции и
сигналинга цитокинов
• Другие иммунологические нарушения
CARCINOGENESIS
TUMOR DISEASE
Дезинтеграция систем мозга
Anterior
pituitary gland
Sympathetic
spinal nerves
Oxidative-nitrosative stress
Stress Hormones (glucocorticoids, catecholamines)
Adrenal cortex Adrenal medulla
Hypothalamus
Ischemia of tissues. Metabolic disorders
DOUBLE PSYCHOTRAUMA
Massive psychotrauma. events before the diagnosis of cancer
The diagnosis of cancer is a massive inexhaustible psychotrauma
PSYCHO-EMOTIONAL DISORDERS
Anxiety and Depression
SUPPRESSION of
specific antitumor
activity of the immune
system

Tumor-associated antigenes:
Larinated Melanoma Cells, BRO
line 25103 in one dose(50 µL)
Evaluation of the result (in 12
hours):
0-5 mm – low activity
5-10 mm – medium activity
>10 mm – high activity
SPECIFIC ANTI-TUMOR DIAGNOSTIC TEST
unstimulated native specific skin reaction of delayed type hypersensitivity on tumor-associated
antigens
Intradermal administration of
tumor-associated antigens
Evaluation of skin reaction

0
1
2
3
4
5
6
7
8
9
ДО n=90 ПОСЛЕ
n=45
P= 0.0001
ГЗТ-реакция
(диаметргиперемии,мм)
НЕТ
Изменений уровня концентраций
30 цитокинов в нативной плазме
и 24ч супернатантах крови
(p>0.05)
НЕТ
Изменений дневного уровня
кортизола (p>0.05)
НЕТ
Корреляций кожной ГЗТ-реакции
с уровнем концентраций 30
цитокинов в нативной плазме и
24ч супернатантах крови
(p>0.05)
НЕТ
Корреляций кожной ГЗТ-реакции
с дневным уровнем кортизола
(p>0.05).
ДА
Корреляции кожной ГЗТ-реакции
с Тревогой (r=-0.34, p=0.028)
SUPPRESSION OF SPECIFIC ANTI-TUMOR ACTIVITY OF THE
IMMUNE SYSTEM IN PATIENTS WITH MALIGNANT TUMORS
WITH PSYCHOGENEOUS ANAMNESIS IS PSYCHOGENICALLY
CONDITIONED AND REVERSABLE
The course of malignant tumorous disease with a psychogenic
anamnesis depends on the state of the higher nervous activity
TREATMENT OF MALIGNANT TUMOR DISEASE WITH
PSYCHOGENIC ANAMNESIS DEMANDS MANDATORY
CORRECTION OF VIOLATIONS OF HIGHER NERVOUS ACTIVITY

1. Psychogenic history - significant, including massive
psychotraumatic events before the diagnosis of cancer (death
of close people, divorce, disability in the family, frequent
family conflicts, change of residence, work, etc.)
2. The presence of psycho-emotional disorders
3. Inhibition of specific antitumor activity of the immune
system
Bukhtoyarov OV, Samarin DM. Psychogenic Carcinogenesis.
In: Mohan R, ed. Advances in Cancer Management. Rijeka: InTech, 2012:17–56.

The study of the method of immunodiagnosis of the risk of recurrence /
progression of malignant tumors saw participation of 133 onco patients with
24 kinds of malignant tumors :
breast cancer, ovarian cancer, melanoma, kidney cancer, stomach cancer, breast
cancer, ovarian cancer, melanoma, kidney cancer, stomach cancer, rectal cancer,
colon cancer, cervical cancer, uterine cancer, sigmoid cancer, bladder cancer, lung
cancer, thyroid cancer, laryngeal cancer, vulvar cancer, prostate cancer, oral mucosa
cancer, basal cell carcinoma, sarcoma, mesothelioma, lymphoma, lymphosarcoma,
acute myelogenous leukemia, non-Hodgkin's lymphoma.
RESULTS:
1. The cutaneous reaction to tumor-associated antigens from 0 mm to 5 mm
is associated with the recurrence / progression of malignant tumors, n = 97 (r =
0.83, p <0.0001)
2. In case of skin reaction to tumor-associated antigens in the range from 0
mm to 5 mm, the probability of recurrence / progression of malignant tumor
disease is 95 ± 3%.
3. Since the evaluation of the skin reaction tumor-associated antigens, the
average time to clinico-instrumental verification of the recurrence / progression
of cancer is 5.5 ± 3.15 months.
METHOD OF IMMUNODIAGNOSTICS OF THE RISK OF RECURRENCE OF MALIGNANT TUMORS
Russian Immunological Journal, 2016. - Vol. 10, No. 2. - P. 534-536

РАНА
ВОСПАЛЕНИЕ ХРОНИЧЕСКОЕ
ВОСПАЛЕНИЕ
НЕЗАЖИВАЮЩАЯ
РАНА
РЕПАРАЦИЯ
(ЗАЖИВЛЕНИЕ)
РАКОВАЯРЕПАРАТИВНАЯ
ЛОВУШКА

1. Diagnosis of anxiety and
depressive disorders
2. Effective treatment of psycho-
emotional disorders
3. Correction of hyper-
sympathicotonia
1. Evaluation of inhibition of
antitumor immunity activity
2. Activation of antitumor immunity
1. Diagnosis of chronic
inflammatory diseases
2. Effective treatment of chronic
inflammation

Patient S., 43 y.o.
Bronchoalveolar cancer
(adenocarcinoma), stage IV
27.01.2017
3038 2017/25/09 10:06:392017/27/01 11:27:21

Bukhtoyarov O.V., Samarin D.M.
Psychogenic Carcinogenesis.
In: Mohan, R., Ed., (2012). Advances in Cancer Management, InTech, Rijeka, pp. 17-56.
http://www.intechopen.com/books/advances-in-cancer-management/psychogenic-carcinogenesis
Pathogenesis of Cancer: Cancer Reparative Trap.
Journal of Cancer Therapy. (2015). Vol.6 (5), pp. 399-412.
http://www.academicjournals.org/IJMMS
Psychogenic Activation Phenomenon of Specific Anti-Tumor Immunity in Cancer Patients.
International Journal of Medicine and Medical Sciences. (2013). Vol. 5 (4), pp. 198-205.
http://www.academicjournals.org/IJMMS
Advanced Cancer Treatment – An Original Approach.
In: Rangel, L. and Silva, I.V., Eds., (2015). Updates on Cancer Treatment, InTech, Rijeka.
http://www.intechopen.com/articles/show/title/advanced-cancer-treatment-an-original-approach
Psychogenic Carcinogenesis: Carcinogenesis is Without Exogenic Carcinogens.
Medical Hypotheses. (2009). Vol. 73 (4), pp. 531-536.
http://www.ncbi.nlm.nih.gov/pubmed/19570616

The role of the psychogenic factor in the development of malignant tumours

The role of the psychogenic factor in the development of malignant tumours

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to The role of the psychogenic factor in the development of malignant tumours

Similar to The role of the psychogenic factor in the development of malignant tumours (20)

More from Nata Chalanskaya

More from Nata Chalanskaya (18)

Recently uploaded

Recently uploaded (20)

The role of the psychogenic factor in the development of malignant tumours